If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

CEREBYX® Drug Interactions (fosphenytoin sodium)

7 DRUG INTERACTIONS

Fosphenytoin is extensively bound to human plasma proteins. Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin. Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering CEREBYX with other drugs that significantly bind to serum albumin. The most significant drug interactions following administration of CEREBYX are expected to occur with drugs that interact with phenytoin. Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement. Phenytoin is metabolized by hepatic cytochrome P450 enzymes CYP2C9 and CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity. Monitoring of phenytoin serum levels is recommended when a drug interaction is suspected.

Phenytoin or CEREBYX is a potent inducer of hepatic drug-metabolizing enzymes.

7.1 Drugs that Affect Phenytoin or CEREBYX

Table 6 includes commonly occurring drug interactions that affect phenytoin (the active metabolite of CEREBYX) concentrations. However, this list is not intended to be inclusive or comprehensive. Individual prescribing information from relevant drugs should be consulted.

The addition or withdrawal of these agents in patients on phenytoin therapy may require an adjustment of the phenytoin dose to achieve optimal clinical outcome.

Table 6. Drugs That Affect Phenytoin Concentrations
Interacting Agent Examples
*
The induction potency of St. John's wort may vary widely based on preparation.
Drugs that may increase phenytoin serum levels
  Antiepileptic drugs Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate
  Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole
  Antineoplastic agents Capecitabine, fluorouracil
  Antidepressants Fluoxetine, fluvoxamine, sertraline
  Gastric acid reducing agents H2 antagonists (cimetidine), omeprazole
  Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim
  Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin
Drugs that may decrease phenytoin serum levels
  Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate
  Antiviral agents Fosamprenavir, nelfinavir, ritonavir
  Antiepileptic drugs Carbamazepine, vigabatrin
  Other Chronic alcohol abuse, diazepam, diazoxide, folic acid, reserpine, rifampin, St. John's wort,* theophylline
Drugs that may either increase or decrease phenytoin serum levels
  Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid

7.2 Drugs Affected by Phenytoin or CEREBYX

Table 7 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of CEREBYX). However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The addition or withdrawal of phenytoin during concomitant therapy with these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome.

Table 7: Drugs Affected by Phenytoin
Interacting Agent Examples
*
The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable.
Drugs whose efficacy is impaired by phenytoin
  Azoles Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole
  Antineoplastic agents Irinotecan, paclitaxel, teniposide
  Delavirdine Phenytoin can substantially reduce the concentrations of delavirdine. This can lead to loss of virologic response and possible resistance [see Contraindications (4)].
  Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown.
  
Prevention or Management: Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher.
  Warfarin Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin.
  Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D
Drugs whose level is decreased by phenytoin
  Antiepileptic drugs* Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine
  Antilipidemic agents Atorvastatin, fluvastatin, simvastatin
  Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir
Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir
  Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil
  Other Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine

7.3 Drug/Laboratory Test Interactions

Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations following CEREBYX administration.

 
Did you find an answer to your question? Yes No

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CEREBYX® Quick Finder

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

*9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch